26.22USD+1.71%Mkt Cap: 1.46B USDP/E: —Last update: 2026-05-26
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.46B USD
Enterprise Value1.13B USD
Revenue (TTM)20.00M USD
Gross Profit20.00M USD
Net Income (TTM)-131.12M USD
Revenue/Share0.4060 USD
Last Price26.22 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees141
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.79
PEG—
EV/EBITDA-8.60
EV/Revenue56.70
P/S71.26
P/B3.72
EPS (TTM)-2.35
EPS (Forward)-3.31
52W Range
9.73238% of range53.65
52W High53.65 USD
52W Low9.732 USD
Profitability
Gross Margin100.00%
Oper. Margin-132.76%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-36.94%
ROA-33.02%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-111.94M USD
CapEx (TTM)794.00K USD
FCF Margin-408.52%
FCF Yield-5.60%
Net Debt-291.16M USD
Net Debt/EBITDA2.21
Balance Sheet
Debt/Equity0.07
Current Ratio17.88
Quick Ratio17.62
Book Value/Sh6.928 USD
Cash/Share6.367 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)62.55 USD
Target Range46.00 USD – 110.00 USD
# Analysts11
Ownership
Shares Out.55.35M
Float37.15M
Insiders1.46%
Institutions95.37%
Short Interest
Short Ratio4.6d
Short % Float8.87%
Short % Out.7.87%
Shares Short4.35M
Short (prev mo.)3.89M
Technical
SMA 5031.18 (-15.9%)
SMA 20032.74 (-19.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)680.94K
Avg Vol (10d)489.33K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—